Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
Daniel R. Gomez(Cedars-Sinai Medical Center), John V. Heymach(The University of Texas MD Anderson Cancer Center), Chad Tang(The University of Texas MD Anderson Cancer Center), Xin Shelley Wang(The University of Texas MD Anderson Cancer Center), Robert C. Doebele(Aurora University), Alexander V. Louie(London Health Sciences Centre), Qiuling Shi(Chongqing Medical University), Ferdinandos Skoulidis(The University of Texas MD Anderson Cancer Center), Brian D. Kavanagh(University of Colorado Denver), Anne S. Tsao(The University of Texas MD Anderson Cancer Center), Boris Sepesi(HealthONE), José A. Karam(The University of Texas MD Anderson Cancer Center), William N. William(The University of Texas MD Anderson Cancer Center), Stephen G. Swisher(The University of Texas MD Anderson Cancer Center), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Rong Ye(The University of Texas MD Anderson Cancer Center), D. Ross Camidge(University of Colorado Denver), Mike Hernández(The University of Texas MD Anderson Cancer Center), David A. Palma(Western University), Jianjun Zhang(The University of Texas MD Anderson Cancer Center), Ritsuko Komaki(The University of Texas MD Anderson Cancer Center), Laurie E. Gaspar(University of Colorado Cancer Center), Don L. Gibbons(The University of Texas MD Anderson Cancer Center)
Cited by 1,082
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k